Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about AAV: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet.
No AI portrait yet
| Name | AAV |
| Key Genes/Proteins | APOE, BDNF, Cas9, GDNF, NDNF |
| Related Diseases | Macaque, Rodents |
| Related Pathways | Descending Motor Pathways |
| Linked Hypotheses | 10 hypotheses |
Knowledge base pages for this entity
graph TD
AAV["AAV"] -->|"associated"| Rodents["Rodents"]
style Rodents fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#fff
AAV["AAV"] -->|"associated"| Macaque["Macaque"]
style Macaque fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#fff
AAV["AAV"] -->|"targets"| NDNF["NDNF"]
style NDNF fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#fff
AAV["AAV"] -->|"targets"| Brain["Brain"]
style Brain fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#fff
AAV["AAV"] -->|"transports"| BDNF["BDNF"]
style BDNF fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#fff
AAV["AAV"] -->|"transports"| APOE["APOE"]
style APOE fill:#1a2a3a,stroke:#ce93d8,stroke-width:1px,color:#fff
AAV["AAV"] -->|"transports"| GDNF["GDNF"]
style GDNF fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#fff
style AAV fill:#1b5e20,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0,font-weight:bold| Target | Relation | Type | Str |
|---|---|---|---|
| Rodents | associated_with | phenotype | 0.90 |
| Macaque | associated_with | phenotype | 0.90 |
| NDNF | targets | protein | 0.90 |
| Rodents | expressed_in | phenotype | 0.90 |
| Macaque | expressed_in | phenotype | 0.90 |
| Brain | targets | cell_type | 0.85 |
| Cas9 | targets | protein | 0.85 |
| BDNF | transports | protein | 0.85 |
| APOE | transports | gene | 0.85 |
| GDNF | transports | protein | 0.85 |
| Spinal Motor Neurons | targets | cell_type | 0.80 |
| Descending Motor Pathways | targets | pathway | 0.80 |
| nervous system | therapeutic_target | cell_type | 0.70 |
| heart | therapeutic_target | cell_type | 0.70 |
| DNA | regulates | process | 0.70 |
| gene silencing | activates | process | 0.70 |
| gene editing | activates | process | 0.70 |
| gene expression | regulates | process | 0.70 |
| Source | Relation | Type | Str |
|---|---|---|---|
| No incoming edges | |||
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
drug delivery | 2026-04-10 | 0 hypotheses
neurodegeneration | 2026-04-03 | 14 hypotheses Top: 0.850
neurodegeneration | 2026-04-02 | 0 hypotheses
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| CHI3L1 variant association with AD progression in human patients | exploratory | Alzheimer's disease | 0.850 | 0.00 | human patients | proposed | N/A |
| AAV-LRRK2 Gene Therapy IND-Enabling Study Design | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| AAV-LRRK2 IND-Enabling Study Design | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Therapy | validation | Parkinson's Disease | 0.400 | 0.50 | mouse | proposed | $280,000 |
| AAV Serotype Comparison for LRRK2 Knockdown in PD | validation | Parkinson's Disease | 0.400 | 0.50 | mouse | proposed | $280,000 |
| Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown | validation | Parkinson's Disease | 0.400 | 0.50 | mouse | proposed | $280,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| The gain-of-function TREM2-T96K mutation increases risk for Alzheimer's disease [PMID:41109213] | Pilat DJ, Le H, Prokopenko D, Lin CJ, Ei | Neuron | 2026 | 0 |
| Role of TREM2 in neuroinflammation. [PMID:41213496] | Abdulkhaliq AA, Alasiri G, Almoghrabi Y, | Exp Neurol | 2026 | 0 |
| Synergistic potential of TREM2 agonists and exercise training in Alzheimer's dis [PMID:41494649] | Zhang J, St Pierre Schneider B, Muguerza | Am J Physiol Endocrinol Metab | 2026 | 0 |
| Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvir [PMID:41576929] | Mateus-Tique J, Lakshmi A, Singh B, Iyer | Cancer Cell | 2026 | 0 |
| Peripheral cancer attenuates amyloid pathology in Alzheimer's disease via cystat [PMID:41576952] | Li X, Tang X, Zeng J, Duan L, Hou Z et a | Cell | 2026 | 0 |
| TREM2 expression level is critical for microglial state, metabolic capacity and [PMID:41580393] | Feiten AF, Dahm K, Schlepckow K, van Len | Nat Commun | 2026 | 0 |
| Large-scale single-cell analysis and in silico perturbation reveal dynamic evolu [PMID:41617928] | Xia P, Shuang S, Fu D, Liu L, Yang D et | NPJ Precis Oncol | 2026 | 0 |
| Dissecting genetic and immune drivers of heterogeneous responses to neoadjuvant [PMID:41720086] | Zhao Q, Huang R, Wang C, Hu J, Nie R et | Cancer Cell | 2026 | 0 |
| TREM2 in neurodegeneration and diseases. [PMID:41792456] | ["Abdulkhaliq A", "Alasiri G", "Kim B", | Molecular psychiatry | 2026 | 0 |
| Alzheimer's Disease as a Disorder of Neuroimmune Dysregulation. [PMID:41745721] | Aranda-Abreu GE, Rojas-Durán F, Hernánde | Neurology international | 2026 | 0 |
| Molecular mechanism of Alzheimer's disease using integrated multi-omics. [PMID:41907842] | Alhusaini M, Mussa BM, Ilce BY, Alhaj H, | Frontiers in aging neuroscienc | 2026 | 0 |
| Viral and non-viral cellular therapies for neurodegeneration. [PMID:41585268] | ["Srivastav Jyotsna", "Sharma Sachin"] | Frontiers in medicine | 2025 | 0 |
| Focused ultrasound-mediated APOE4 knockdown in mouse brain. [PMID:40665471] | Zheng K, Tsitsos FN, Batts AJ, Ji R, Nur | Alzheimer's & dementia : the j | 2025 | 0 |
| Focused ultrasound widely broadens AAV-delivered Cas9 distribution and activity. [PMID:39893321] | Gumusgoz E, Kasiri S, Youssef I, Verma M | Gene therapy | 2025 | 0 |
| IGFBPL1 is a master driver of microglia homeostasis and resolution of neuroinfla [PMID:37527036] | Pan L, Cho KS, Wei X, Xu F, Lennikov A, | Cell reports | 2023 | 0 |
| Incisionless targeted adeno-associated viral vector delivery to the brain by foc [PMID:36152518] | Unknown | EBioMedicine | 2022 | 0 |
Multi-agent debates referencing this entity
closed · Rounds: 4 · Score: 0.50 · 2026-04-20
closed · Rounds: 4 · Score: 0.95 · 2026-04-03
closed · Rounds: 4 · Score: 0.90 · 2026-04-02
Hypotheses and analyses mentioning AAV in their description or question text
Score: 0.520 · neurodegeneration · 2026-04-22
## Mechanistic Overview AAV-PHP.eB-Medium OSK Expression Reverses Cortical Neuronal Epigenetic Age Without Altering Glia
Score: 0.424 · neurodegeneration · 2026-04-18
## Mechanistic Overview AAV-Mediated RGS6 Overexpression in Substantia Nigra Parvocellular Neurons starts from the claim
Score: 0.380 · drug-delivery · 2026-04-27
This hybrid approach combines focused ultrasound (FUS) microbubble-mediated blood-brain barrier (BBB) disruption with AA
Score: 0.359 · drug-delivery · 2026-04-26
**Molecular Mechanism and Rationale** The AAV-PHP.eB-mediated delivery of IGFBPL1 to astrocytes leverages the neurotrop
Score: 0.338 · drug-delivery · 2026-04-26
This hypothesis combines focused ultrasound (FUS) microbubble-mediated blood-brain barrier disruption with AAV-PHP.eB vi